Lantern Pharma Inc.
As of Oct 22, 2026, Lantern Pharma is in Stage 4, the downtrend phase, now in week 8 (since Sep 1, 2026). It closed at $0.64, 84.6% below its 52-week high and below its 200-day average, which is falling.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LTRN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LTRN among Biotechnology484th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …484 | LTRN | Stage 4 · wk 8 | 10 | −53.9% |
Lantern Pharma: quick answers
What stage is Lantern Pharma in?
As of Oct 22, 2026, Lantern Pharma (LTRN) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 1, 2026 and is in week 8. What the four stages mean
Is Lantern Pharma in an uptrend?
No. Lantern Pharma is in a Stage 4 downtrend. It trades 74.8% below its 200-day average, which is falling.
How far is Lantern Pharma from its 52-week high?
Lantern Pharma closed at $0.64 on Oct 22, 2026, 84.6% below its 52-week high of $4.17. Its 52-week low is $0.64.
How has Lantern Pharma performed over the past year?
As of Oct 22, 2026, Lantern Pharma is down 83.9% over the past year and down 79.4% so far in 2026.
Which sector and industry is Lantern Pharma in?
Lantern Pharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.